Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 1363 results for social care

  1. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

  2. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

  3. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  4. Guidance executive

    NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.

  5. Published guidance, NICE advice and quality standards

    Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards

  6. Mental wellbeing at work (NG212)

    This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

  7. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

  8. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

  9. NICE quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards

  10. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

  11. Asthma (QS25)

    This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.

  12. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date:  04 June 2026

  13. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

  14. Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

    In development Reference number: GID-TA11115 Expected publication date: TBC

  15. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026